Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study

• Published in: Diabetology international Vol. 10; no. 2; pp. 148 - 152
• Main Authors: Makino, Hisashi, Matsuo, Miki, Hishida, Ai, Koezuka, Ryo, Tochiya, Mayu, Ohata, Yoko, Tamanaha, Tamiko, Son, Cheol, Miyamoto, Yoshihiro, Hosoda, Kiminori
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 15.04.2019; Springer Nature B.V
• Subjects: 8-Hydroxydeoxyguanosine; Albumin; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Dipeptidyl-peptidase IV; Endocrinology; Excretion; Fatty acid-binding protein; Inflammation; Kidney diseases; Kidneys; Low density lipoprotein; Malondialdehyde; Medicine; Medicine & Public Health; Metabolic Diseases; Oxidation; Oxidative stress; Peptidase; Renal function; Short Communication; Oxidative stress; Tubulointerstitial injury; DPP-4 inhibitor; Diabetic kidney disease
• ISSN: 2190-1678; 2190-1686
• DOI: 10.1007/s13340-018-0376-9

Background Dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used for the treatment of type 2 diabetes and have been previously shown to prevent diabetic renal injury via various mechanisms, including the attenuation of oxidative stress. Therefore, we hypothesized that linagliptin, a DPP-4 inhibitor, attenuates oxidized stress and diabetic renal injury. Methods In total, 30 patients with type 2 diabetes who were undergoing treatment with linagliptin (5 mg) during the 3-month study period were enrolled. Oxidative stress markers [serum malondialdehyde-modified LDL (MDA-LDL) and urinary 8-hydroxydeoxyguanosine (8-OHdG)], an inflammatory marker (high-sensitive CRP), urinary albumin excretion, estimated GFR, and a urinary tubulointerstitial injury marker [urinary liver-type fatty acid-binding protein (L-FABP)] were evaluated at baseline and after 3 months of treatment. Results Following linagliptin treatment, serum MDA-LDL, serum HbA1c, and urinary L-FABP levels significantly decreased, while urinary 8-OHdG tended to decrease. In contrast, 1,5-AG levels increased, and high-sensitive CRP and urinary albumin excretion remained unchanged. Conclusion In this study, we demonstrated that linagliptin partially attenuated oxidative stress. We also demonstrated that linagliptin treatment reduced urinary L-FABP excretion, suggesting that renal tubule-interstitial injury may be attenuated by linagliptin (UMIN 000015308).